Contineum TherapeuticsCTNM
Recorded

Contineum Therapeutics Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration23 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Thanks. Happy to moderate this catch-up chat with Carmine Stengone, President and CEO of Contineum Therapeutics. Always great to see you. Maybe we'll have Carmine just give a quick sort of overview and update on Contineum and the IPF program, and then we'll do Q&A.

Carmine StengonePresident and CEO

Thanks a lot. Absolutely. Sean, Stifel and Paul, thanks again for inviting us to the conference.

Carmine StengonePresident and CEO

A little bit about Contineum. We are a small molecule biopharmaceutical company based in San Diego. The main focus of the company is fibrosis and inflammation. We have one internally derived asset that is currently in a phase II clinical study, that is PIPE-791. The main focus for this clinical study is idiopathic pulmonary fibrosis, and the target is LPA1. I'm sure that a lot of people have heard recently about the admilparant data, and we believe that we have a compound that is very competitive with theirs, with multiple differentiators, and it's not the worst case having a pharma starting build the market before we get there. We also have a program that is partnered with Johnson & Johnson, again, internally derived. This is PIPE-307. It's a first-in-class inhibitor of the M1 receptor.

Carmine StengonePresident and CEO

J&J has brought that into an MDD study, which recently read out, and we can talk about that a little bit later. We're waiting on potential next steps with that program as well.

Operator

Great. Well, yeah, I think we'll probably spend most of our time on IPF. Just to kind of set the stage, do you want to review the admilparant top line, and what were your main takeaways? I know there's a lot we can unpack.

Carmine StengonePresident and CEO

Yeah. It's hard to interpret a press release that had two lines on the data. We don't know what we don't know. We don't know the effect size. We don't know the confidence intervals. We don't know the P values. What they did disclose in their study, in my opinion, is unambiguous validation of the target. The admilparant phase II study was about 1,200 patients over 52 weeks with a twice-daily dosed LPA1 receptor antagonist, and they brought in two different doses to the study, a 60 milligram BID, which is the top dose that they tested in their phase II, as well as doubling that dose, so introducing a new dose into the phase III at 120 milligrams BID. Really, the takeaway that we got from this was, again, clinical validation is now established with this target in a phase III for the first time.

Carmine StengonePresident and CEO

We've had issues with other programs around this target, including a previous BMS program, having issues before heading into phase III. They also disclosed that they hit statistical significance and clinical efficacy in the 60 milligram BID dose group. They did not hit stat sig at the 120, but they did disclose that they saw a reduction in FVC decline relative to placebo out of that dose group too. I think there's a lot of question marks that hopefully will be answered in the near future, and all likelihood, we're probably waiting till ATS to get all of the information.

Operator

Cool. When's that for people?

Operator

May. Okay. Maybe just to start, is it surprising that there wasn't a linear dose response here?

Carmine StengonePresident and CEO

I don't know that it was response. I don't know that it was anticipated. I think that based on what we know about that molecule, we believe that the receptor occupancy and the target coverage that they have is pretty similar between the 60 mg BID dose group and the 120 mg BID dose group. What we don't know is what was the difference between the two doses, and could this be driven by, again, target coverage? Could it be driven by tolerability associated with some of the properties of this molecule which we work around?

Operator

Right. These will be the questions for the actual presentation.

Operator

Absolutely. Yeah. Okay. Makes sense.

Operator

Maybe I can sort of throw at you some of the inferences people are trying to make and see if you pass the smell test, which I'm sure you've heard. One is that, I think there's this inference out there, it's like, "Well, if this dose hit and the other one didn't hit, then the effect size must not be that big." What would you say to that?

Carmine StengonePresident and CEO

I don't know that that makes a whole lot of sense, obviously, without seeing what the data is. Their effect size hit statistical significance and it's clinically relevant. This is the first time an LPA1 receptor antagonist got through this hurdle. If you look at the contemporary clinical studies, so in that I'm including TYVASO, I'm including nerandomilast, even nintedanib. The focus here is trying to have a 50% reduction in FVC decline relative to placebo, and all of these seem to fall within that same category. I think nerandomilast was at about 40%, TYVASO was in the 50% range. I would expect this to fall within that same category, but some of the key differentiators that this mechanism has is there are no overt tox issues and tolerability issues.

Carmine StengonePresident and CEO

With nerandomilast, obviously, there's a little bit of a GI signal that prevents combination therapy, and that's where everybody wants to move within IPF, is the combination therapies that can drive the full impact of all of these targets. We expect that BMS will have a similar signal to those. We're also really interested in knowing what they did on the secondary endpoints, because that is something that no other program has been able to hit on, and that is acute exacerbations, the functional composite around this, cough. We're bullish on the target itself. We think that there's maybe some compound properties that are unknown around BMS that have driven the change between 60 and 120. In my opinion, I think that the target coverage is pretty similar, and that is what's driving this. We also don't know the SAP, right?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day